Q2 FY2026 · ended Jun 30, 2026 · Revenue $343,639 · Filed Aug 13, 2026
Scienture Holdings, Inc. (SCNX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $343,639 and a net loss of $2.8 million. As of Jun 30, 2026 it held $8.2 million in cash and investments and $2,546 in total debt.
Revenue
$343,639
Net income
$-2.82M
+58.0% vs year-ago quarter
Operating cash flow
$-3.13M
-54.0% vs year-ago quarter
Free cash flow
$-2.91M
+46.1% vs prior quarter
EPS
$-0.07
+85.4% vs year-ago quarter
Dividend per share
None
Shares outstanding
41.06M
+154.6% vs year-ago quarter
Net cash
$8.19M
Q2 FY2026
Operating margin
-4878.9%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SCNX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Commack, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1382574
- Former names
- TRxADE HEALTH, INC (until Aug 28, 2024); TRXADE GROUP, INC. (until May 28, 2021); XCELLINK INTERNATIONAL INC. (until Jan 31, 2014); Bluebird Exploration Co. (until Dec 10, 2008)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $343,639 | $56,325 | -$168,699 | $590,050 | $0 |
| Operating income | -$2.7M | -$3.5M | -$29.5M | -$4.4M | -$5.2M |
| Net income | -$2.8M | -$3.4M | -$28.1M | -$3.6M | -$6.7M |
| Diluted EPS | -$0.07 | -$0.08 | -$1.52 | -$0.19 | -$0.48 |
| Operating cash flow | -$3.1M | -$2.9M | -$5.2M | -$3.2M | -$2.0M |
| Total assets | $87.7M | $80.7M | $84.2M | $104.8M | $84.2M |
| Total liabilities | $23.6M | $13.8M | $14.1M | $22.2M | $26.4M |
| Stockholders' equity | $64.1M | $66.8M | $70.1M | $82.7M | $77.9M |
| Cash and investments | $8.2M | — | $6.7M | — | — |
| Total debt | $2,546 | $10,004 | $24,137 | $2.0M | $3.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Nov 3, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Results of operations, Listing notice
|
Oct 19, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Regulation FD disclosure
|
Oct 7, 2026 | Oct 5, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 14, 2026 | Sep 14, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 20, 2026 | Aug 14, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
All 507 Scienture Holdings, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.